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Marinesco-Sjo¨gren syndrome is a rare autosomal recessive multisystem disorder featuring cerebellar ataxia, early-onset cata-
racts, chronic myopathy, variable intellectual disability and delayed motor development. More recently, mutations in the SIL1
gene, which encodes an endoplasmic reticulum resident co-chaperone, were identified as the main cause of Marinesco-Sjo¨gren
syndrome. Here we describe the results of SIL1 mutation analysis in 62 patients presenting with early-onset ataxia, cataracts and
myopathy or combinations of at least two of these. We obtained a mutation detection rate of 60% (15/25) among patients with
the characteristic Marinesco-Sjo¨gren syndrome triad (ataxia, cataracts, myopathy) whereas the detection rate in the group of
patients with more variable phenotypic presentation was below 3% (1/37). We report 16 unrelated families with a total of 19
different SIL1 mutations. Among these mutations are 15 previously unreported changes, including single- and multi-exon
deletions. Based on data from our screening cohort and data compiled from the literature we found that SIL1 mutations are
invariably associated with the combination of a cerebellar syndrome and chronic myopathy. Cataracts were observed in all
patients beyond the age of 7 years, but might be missing in infants. Six patients with SIL1 mutations had no intellectual
disability, extending the known wide range of cognitive capabilities in Marinesco-Sjo¨gren syndrome to include normal intelli-
gence. Modestly constant features were somatic growth retardation, skeletal abnormalities and pyramidal tract signs.
Examination of mutant SIL1 expression in cultured patient lymphoblasts suggested that SIL1 mutations result in severely reduced
SIL1 protein levels irrespective of the type and position of mutations. Our data broaden the SIL1 mutation spectrum and confirm
that SIL1 is the major Marinesco-Sjo¨gren syndrome gene. SIL1 patients usually present with the characteristic triad but cataracts
might be missing in young children. As cognitive impairment is not obligatory, patients without intellectual disability but a
Marinesco-Sjo¨gren syndrome-compatible phenotype should receive SIL1 mutation analysis. Despite allelic heterogeneity and
many families with private mutations, the phenotype related to SIL1 mutations is relatively homogenous. Based on SIL1
expression studies we speculate that this may arise from a uniform effect of different mutations on protein expression.
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Introduction
Marinesco-Sjo¨gren syndrome (MIM 248800) is a long-recognized
autosomal recessively inherited, infantile-onset multisystem dis-
order that affects brain, eyes and skeletal muscles. The clinical
triad of bilateral cataracts, ataxia and intellectual disability was
noted in the first half of the last century (Moravcsik, 1904;
Marinesco et al., 1931; Sjo¨gren, 1947) and later confirmed in a
series of additional reports. Pathoanatomical and brain imaging
studies revealed cerebellar atrophy as the cause of the cerebellar
syndrome (Todorov, 1965; Georgy et al., 1998). From histopatho-
logical and neurophysiological investigations chronic myopathy
emerged as an additional feature (Chaco, 1969; Herva et al.,
1987) and electron microscopy revealed particular electron-dense
membranous structures around degenerating myonuclei (Herva
et al., 1987; Sewry et al., 1988). Hypergonadotropic hypogonad-
ism, skeletal abnormalities and short stature are additional features
that have been reported with variable frequency (Berg and Skre,
1976; Brogdon et al., 1996). Although most patients are severely
handicapped, life span in Marinesco-Sjo¨gren syndrome is at least
not drastically reduced as the oldest reported patients are in their
70s (Anttonen et al., 2005). More recently, using positional clon-
ing strategies, we and others have shown that Marinesco-Sjo¨gren
syndrome is caused by homozygous or compound heterozygous
point mutations in the SIL1 gene on chromosome 5q31.2
(Anttonen et al., 2005; Senderek et al., 2005). Following the
two original reports, 14 additional families with SIL1 mutations
have been described in the medical literature (Karim et al.,
2006; Annesi et al., 2007; Anttonen et al., 2008; Eriguchi et al.,
2008; Riazuddin et al., 2009; Takahata et al., 2010; Terracciano
et al., 2012). A subgroup of patients with Marinesco-Sjo¨gren syn-
drome was found to be negative for SIL1 point mutations, sug-
gesting alternative mutation mechanisms or locus heterogeneity
(Senderek et al., 2005; Anttonen et al., 2008).
SIL1, the human homolog of yeast Sil1p (suppressor of the
Dire1 Dlhs1 double mutant number 1), is an evolutionary con-
served, ubiquitously expressed 461 amino-acid N-linked glycopro-
tein (Chung et al., 2002). SIL1 acts as a co-chaperone and
nucleotide exchange factor for the HSP70 (heat-shock protein
70) ATPase BiP (immunoglobulin binding protein, also referred
to as 78-kDa glucose-regulated protein GRP78) (Haas and Wabl,
1983; Munro and Pelham, 1986). BiP is a stress-inducible molecu-
lar chaperone and controls a plethora of essential processes in the
endoplasmic reticulum including translocation of nascent proteins
into the endoplasmic reticulum, accurate subsequent folding of the
newly synthesized proteins in the endoplasmic reticulum lumen,
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elimination of proteins that fail to mature properly, response to cell
stress, and calcium homeostasis (Hendershot, 2004). As at least
some functions of BiP require its ATPase activity, it seems plausible
to assume that the nucleotide exchange factor SIL1 is involved in
the regulation of endoplasmic reticulum-associated processes
through control of the BiP ATPase cycle and that impaired BiP
activation is the relevant pathomechanism in Marinesco-Sjo¨gren
syndrome.
The prominent cerebellar atrophy seen in patients with
Marinesco-Sjo¨gren syndrome is caused by loss of Purkinje and
granule cells (Todorov, 1965; Mahloudji et al., 1972; Skre and
Berg, 1977). The same histopathological findings are present in
the spontaneous mouse mutant woozy, which lacks a functional
Sil1 gene resulting in adult-onset ataxia (Zhao et al., 2005).
However, woozy mice seem to differ from humans with
Marinesco-Sjo¨gren syndrome as no symptoms like cataracts or
myopathy have been described in this animal model. SIL1 is ex-
pressed in all tissues and organs in vertebrates with highest levels
in secretory tissues such as liver, placenta and kidney (Chung
et al., 2002). It remains unknown why loss of SIL1 function in
man and mice does not cause lethality and why certain tissues and
cell types such as cerebellum (in mice and humans), eye and skel-
etal muscle (in humans) are more vulnerable to loss of SIL1 func-
tion than other tissues. As in yeast (Tyson and Stirling, 2000), the
presence of the additional nucleotide exchange factor HYOU1
(also known as ORP150 and GRP170) in various organs of mam-
mals may be able to compensate the loss of SIL1 function. This
hypothesis has recently been supported by the finding that the
cerebellar atrophy in the woozy mouse can be compensated by
over-expression of HYOU1 (Zhao et al., 2010).
Here, we screened a cohort of unselected patients referred for
molecular genetic testing of the SIL1 gene. We extend the pheno-
typic and mutation spectrum in patients with Marinesco-Sjo¨gren
syndrome and suggest inclusion criteria for SIL1 mutation screen-
ing based on compilation of clinical data of all reported patients
with SIL1 mutations.
Materials and methods
Patients
All patients included in this study were referred to our molecular gen-
etic diagnostic laboratory for SIL1 mutation analysis between 2005 and
2011. The general inclusion criteria for this study required definite or
probable clinical evidence of early-onset cataracts, cerebellar atrophy/
ataxia and chronic myopathy (n = 25). We also enrolled a cohort of
patients presenting with two out of the three cardinal features plus at
least one of the following additional features: short stature, intellectual
disability, delayed motor milestones, muscular hypotonia, hypogonad-
ism, peripheral neuropathy, skeletal deformities (e.g. scoliosis, pes
cavus) (n = 37). All biological materials (blood samples, DNA samples,
cell lines, archived specimens of diagnostic muscle biopsies), medical
and neurophysiological reports, clinical photographs, ultrasound
images, and brain MRI scans were obtained under appropriate
informed consent of the patients or their legal guardians. Muscle biop-
sies were processed as described previously (Weis and Schro¨der, 1988,
1989).
SIL1 gene sequence analysis
Primer sets for PCR amplification of human SIL1 coding exons 2–10
(NM_022464.4) with 40 to 50 bp of flanking intronic sequences have
been described previously (Senderek et al., 2005). The resulting PCR
products were subjected to fluorescence-based cycle sequencing using
the BigDye Terminator Cycle Sequencing Ready Reaction Kit, version
3.1 (Applied Biosystems). Samples were run and analysed on an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems). Sequencing elec-
tropherograms were assessed by visual inspection in order to identify
variants.
Identification of SIL1 exon-deletion
mutations
In Patient MSS87.1 we identified a seemingly homozygous mutation in
exon 9 whereas we observed heterozygosity for two variants in exon 3
and intron 4. Based on these findings we assumed that Patient
MSS87.1 might harbour a heterozygous intragenic deletion encom-
passing at least exon 9. High resolution genome wide single-nucleotide
polymorphism array analysis was performed by using an Affymetrix
250K Nsp SNP array (Affymetrix), in accordance with the supplier’s
instructions, and copy-number data were analysed with the Affymetrix
Genotyping Console 3.0.2 software. For confirmation and fine map-
ping of a copy number deviation, we developed quantitative real-time
PCR assays for 12 fragments located in introns 7 and 9 and 3’ of the
SIL1 gene (Fig. 1B). As reference locus, exon 3 of the factor VIII gene
(Wilke et al., 2000) was used. Quantitative real-time PCR was carried
out on an ABI PRISM 7000 sequence detection system (Applied
Biosystems) using the quantitative real-time PCR core kit for SYBR
Green I according to the manufacturer’s protocol (Eurogentec). Data
evaluation was performed using the ABI PRISM 7000 sequence detec-
tion software as described previously (Wilke et al., 2000) and the
ratios of test and reference fragments were calculated to determine
copy numbers of the test fragments. Primers from the fragments
found to be situated just outside the deletion (i.e. fragments yielding
results in favour of two copies) were used in an attempt to amplify the
breakpoint region by long-range PCR.
PCR amplification of SIL1 exon 5 consistently failed in the DNA
sample of the index patient of Family MSS150.1 whereas amplification
of exons 4 and 6 was normal. To obtain further evidence for a pre-
sumed intragenic deletion removing exon 5, total RNA was isolated
from a fresh blood sample of the index patient, reverse transcribed and
used as template for PCR with primers in SIL1 exons 1 and 10
(Fig. 1C). Sequencing of the PCR product was performed using ABI
Prism BigDye technology as described above. At the genomic level,
the extent of the presumed deletion was defined using amplification of
several short 100–200 bp genomic fragments placed every 2–3 kb
within the 25 kb genomic region encompassing intron 4, exon 5 and
intron 5. Primers from fragments found to lie just outside the deletion
(i.e, these fragments yielded amplification in patient’s DNA while frag-
ments situated in the genomic region flanked by these markers gave
no products) were combined to amplify a junction fragment charac-
teristic for the deletion (Fig. 1D). The junction fragment was subjected
to cycle sequencing in order to identify the precise positions of the
deletion breakpoints.
Cell culture and western blotting
Epstein-Barr virus-immortalized B lymphoblast cell lines from control sub-
jects and patients with Marinesco-Sjo¨gren syndrome were established
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Figure 1 SIL1 mutations. (A) Graphical overview of mutations found in this and other studies. Different mutation types are marked with
different symbols. Circles = missense mutations and small in-frame indels; rhombi = nonsense mutations; triangles = frameshift mutations;
squares = splice site mutations; two-sided arrows = exon-deletion mutations. Previously unreported sequence variations identified in this
study are coloured in red. Exon, nucleotide and amino acid numbering is according to NM_022464.4 and NP_071909.1. Introns are not
drawn to scale. AA = amino acid. (B) Heterozygous multi-exon deletion in Patient MSS87.1. Sequencing electropherograms show het-
erozygous variants in exon 3 (rs3088052, open rhombus) and intron 4 (c.353 + 38T4A, open circle) as well as a seemingly homozygous
frameshift mutation c.947dupT, p.R317fs in exon 9 (filled triangle, the electropherogram below represents the wild-type sequence).
A high-density genome-wide single nucleotide polymorphism array (upper left) and copy number analysis of fragments located in the
potential deletion region by quantitative real-time PCR (vertical bars above the schematic representation of the SIL1 gene, red: one copy,
black: two copies) were suggestive of a partial, 68–77 kb deletion involving exons 8–10 (boxed with dotted red lines). Long-range PCR
with primers from the fragments found to be situated just outside the deletion failed to amplify a deletion specific junction fragment
leaving the possibility of a more complex genomic rearrangement although routine-karyotyping had previously shown two normal
chromosomes 5. (C and D) Homozygous exon 5 deletion in Patient MSS150.1. (C) Reverse transcription PCR using patient’s messenger
RNA (P) yielded a shorter 1370-bp fragment (C: control messenger RNA, 1470 bp). Positions of pimers are indicated by arrowheads
underneath the schematic representation of the SIL1 messenger RNA. Sequencing electropherograms representing the normal exon 4/
exon 5 and normal exon 5/exon 6 junctions are shown above the schematic representation of the SIL1 messenger RNA; the exon 4/exon 6
junction resulting from the genomic deletion is shown below. Removal of the 100-bp exon 5 from the mature messenger RNA is predicted
to result in frameshift and premature stop of translation (asterisk). (D) Sequencing of a PCR-amplified deletion-specific junction fragment
at the genomic level. Primers placed in intron 4 and intron 5 of the SIL1 gene yielded a 2.5 kb shorter product when using patient’s (P)
DNA (C: control DNA, 4029 bp). Positions of primers are indicated by arrowheads underneath the schematic representation of the SIL1
gene genomic region (not drawn to scale). The borders of the deletion which encompasses 2660 bp including exon 5 were determined by
DNA sequencing with internal primers. The extent of the deletion is indicated as a grey box.
Marinesco-Sjo¨gren syndrome Brain 2013: 136; 3634–3644 | 3637
according to standard protocols (Tohda et al., 1978). The immortalized
lymphoblasts were cultured in RPMI-1640 growth medium, harvested
by centrifugation (800 rpm, 7 min), washed twice in cold PBS and pel-
leted by centrifugation (14 000 rpm, 5 min, 4C). Cell pellets were
homogenized in lysis buffer (10 mM Tris-HCl, 5 mM EDTA, 150 mM
NaCl, 1% TritonTM X-100) containing protease and phosphatase inhibi-
tors. Post-nuclear supernatants were boiled in sample buffer (80 mM Tris
pH 6.8, 10% glycerol, 2% SDS, 0.002% bromphenol blue), resolved by
SDS–PAGE and electroblotted onto polyvinylidene fluoride membranes
(Hybond-C; GE Healthcare). Immunoblots were developed by incubation
with appropriate antibodies followed by horseradish peroxidase-
phosphatase chemiluminescence detection (ECL; GE Healthcare). The
following antibodies were used: mouse monoclonal anti-SIL1 clone
1F9 (Origene Technologies; dilution 1:1000), mouse monoclonal anti-
GAPDH (Genetex; dilution 1:1000), goat anti-rabbit immunoglobulin
G antibody conjugated to horseradish peroxidase (Invitrogen; dilution
1:5000), goat anti-mouse immunoglobulin G conjugated to horseradish
peroxidase (Invitrogen; dilution 1:5000).
Results
Mutation screening of the SIL1 gene in a diagnostic sample of 62 un-
related, previously unreported index patients with Marinesco-Sjo¨gren
syndrome or Marinesco-Sjo¨gren syndrome-like conditions revealed
pathogenic sequence variants in 16 families of diverse ethnic back-
grounds, representing roughly 25% of the total cohort. The muta-
tion detection rate reached 60% (15/25) in the cohort of patients
presenting with the clinical triad of cerebellar atrophy, myopathy and
cataracts whereas the mutation detection rate was 53% (1/37)
among Marinesco-Sjo¨gren syndrome-like cases (two of the cardinal
features and at least one of the following symptoms: short stature,
intellectual disability, delayed motor milestones, hypotonia, hypo-
gonadism, peripheral neuropathy, skeletal deformities).
We observed a total of 19 different SIL1 mutations consisting of
a missense mutation, a two-amino acid in-frame deletion, seven
frameshift mutations, four nonsense mutations, four nucleotide
changes affecting splice sites and two genomic deletions (Fig. 1
and Table 1). Among these mutations, 15 had not been reported
previously. None of these so far unrecognized changes was pre-
sent in databases containing information on the ‘normal’ variability
of the human genome (dbSNP version 135, www.1000genomes.
org/; 1000 Genomes database, www.ncbi.nlm.nih.gov/projects/
SNP/; Exome Variant Server, evs.gs.washington.edu/EVS/). In
addition, analysis of DNA samples obtained from healthy control
individuals, adjusted to the type of mutation (i.e. at least 100 for
each truncating and at least 400 for each missense mutation), did
not yield any of the identified genotypes. All patients were identi-
fied with bi-allelic mutations, either in the homozygous or com-
pound heterozygous state. When DNA from family members was
available, we observed that the disease phenotype co-segregated
with recessive inheritance of the SIL1 mutations. The parents car-
ried mutations in the heterozygous state, and unaffected siblings
carried either one heterozygous mutation or were homozygous for
the wild-type alleles.
Detailed clinical, electrophysiological and muscle biopsy findings of
23 patients from the 16 families carrying pathogenic SIL1 mutations
are provided in Supplementary Table 1. All patients came to medical
attention with symptoms suggestive of Marinesco-Sjo¨gren syndrome
within the first 5 years of life. Initial presenting symptoms were
nonetheless variable: some patients presented very soon after birth
with severe hypotonia, whereas most showed delay in motor mile-
stones or truncal ataxia when starting to sit or stand, after a normal
neonatal period. The mean age at onset of cataracts was 3.7 years
(1.5 years). Congenital cataracts were only noted in one patient
and the latest manifestation of cataracts was reported at the age of
7 years. In line with this observation, one girl did not show any lens
opacities at the age of 4 years. Apart from this exception, all patients
invariably presented with a cerebellar syndrome, symptoms and signs
of a myopathy and bilateral cataracts. Modestly constant features
were skeletal deformities, somatic growth retardation and pyramidal
tract signs. Mental capacities of patients with SIL1 mutations were
highly variable, ranging from normal (n = 6) over mild (n = 7) to
moderate (n = 8) and severe intellectual disability (n = 2). Other clin-
ical features were only occasionally recorded (e.g. epilepsy or micro-
cephaly) or could only be reasonably assessed in a too small
subgroup of patients to give meaningful figures (e.g. hypogonadism
in postpubertal patients). Although motor development was often
markedly delayed, patients generally became mobile with a walker
or other orthopaedic devices (canes, crutches, braces). Marked atro-
phy of the cerebellum was observed in all patients who received
brain MRI) (Fig. 2B–D). Serum creatine kinase (CK) levels were usu-
ally only slightly or moderately elevated (377  159 U/l). Through a
review of the medical literature we recorded 65 additional patients
with Marinesco-Sjo¨gren syndrome with confirmed SIL1 mutations
(30 families). We combined these data with information from our
patient cohort to determine the relative frequency of signs and
symptoms in SIL1-associated Marinesco-Sjo¨gren syndrome
(Supplementary Table 2 and Fig. 2A).
We reassessed muscle biopsy specimens that had been taken for
diagnostic purposes from four patients with identified SIL1 muta-
tions (MSS33.1, MSS87.1, MSS91.1, and MSS94.1). Histologically
we observed different degrees of degeneration of skeletal muscle
fibres (Fig. 3A): sarcoplasmic vacuoles, often associated with myo-
nuclei, greater-than-normal variability in fibre size, rounded atro-
phic fibres, myofibre hypertrophy and splitting, increased numbers
of internal nuclei, endomysial fibrosis and proliferation of fat
tissue. At the ultrastructural level (Fig. 3B–D), autophagic vacu-
oles, which were often associated with degenerating myonuclei,
were encountered frequently. Several degenerating myonuclei
were surrounded by an electron-dense, membrane-like structure.
This feature was constantly observed in all four muscle biopsies
that were accessible to us. Muscle biopsy findings of 10 additional
patients were available from medical records and were indicative
of a chronic myopathic process. Five biopsy samples had also been
examined by electron microscopy; however, no details concerning
possible nuclear abnormalities were mentioned in the reports.
By immunoblotting, we found that SIL1 levels in lymphoblast
lines of five patients with different SIL1 mutations were substan-
tially reduced compared with the levels in control subjects (Fig. 4).
Importantly, reduced amounts of SIL1 were also seen in patients
with seemingly ‘milder’ mutations [small in-frame deletion
(MSS24.1), missense mutation (MSS32.1) and frameshift mutation
in the last exon which is expected to escape nonsense-mediated
messenger RNA decay (MSS64.1)].
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Discussion
In this study we report the results of SIL1 mutation screening in
patients who were referred to our laboratory for molecular genetic
testing of Marinesco-Sjo¨gren syndrome during the past 5 years.
Our study confirms the previous findings of mutations in SIL1
being the major cause of Marinesco-Sjo¨gren syndrome. Our data
extend the spectrum of Marinesco-Sjo¨gren syndrome-causing SIL1
mutations, increasing the number of different mutations to 36 and
bringing the total number of published molecular-genetically
confirmed families to 46 (88 patients). Based on these data we
describe the relative frequency of signs and symptoms of patients
with Marinesco-Sjo¨gren syndrome with identified SIL1 mutations.
This information may help to decide which patients should
undergo SIL1 mutation analysis.
We confirm that Marinesco-Sjo¨gren syndrome caused by SIL1
mutations is a panethnic condition. Some SIL1 mutations have
been found as recurrent events in more than one family and
four mutations have been found repeatedly (53 ) in independ-
ent families (p.R111X, p.D170fs, p.R317fs, p.F345fs, Table 1).
Table 1 SIL1 mutations in patients with Marinesco-Sjo¨gren syndrome identified in this study and earlier reports
Location Nucleotide change Effect on coding sequence Ethnic origin References
Exon 3 c.178G4T p.E60X Vietnam Senderek et al., 2005
Exon 3 c.212dupA p.H71fs France Anttonen et al., 2005
Intron 3 c.244 + 1G4A splice error predicted Turkey This study
Exon 4 c.274C4T p.R92W Pakistan Riazuddin et al., 2009
Exon 4 c.302_303delAG p.E101fs Pakistan This study
Exon 4 c.331C4T p.R111X Iran, Turkey, Italy Senderek et al., 2005
Anttonen et al., 2005
Annesi et al., 2007
Terracciano et al., 2012
Exon 4 c.347delG p.G116fs Vietnam Senderek et al., 2005
Exon 5 chr5:g.138376244_138378903del p.L119fs India This study
Exon 5 c.424delG p.A142fs Germany This study
Exons 6, 7 chr5:g.138311133_138369401delinsTGCA p.A152fs Japan Takahata et al., 2010
Exon 6 c.460C4T p.Q154X France This study
Exon 6 c.506_509dupAAGA p.D170fs Finland, Sweden, Norway Anttonen et al., 2005
Exon 6 c.603_607delGAAGA p.E201fs Japan Takahata et al., 2010
Intron 6 c.645 + 1G4A p.A152_Q215del Turkey, Argentina Senderek et al., 2005
This study
Intron 6 c.645 + 2T4C p.A152_Q215del Sweden Anttonen et al., 2005
Exon 7 c.691_696delGTGATC p.V231_l232del Turkey This study
Intron 7 c.768-1G4A p.S256fs Italy This study
Exons 8, 9, 10 chr5:g.(138271912_138277581)
_(138345106_138349134)del
p.S256_R461del Russia This study
Exon 8 c.811C4T p.Q271X Turkey This study
Exon 9 c.866dupT p.L290fs France This study
Exon 9 c.934G4A p.G312R USA This study
Exon 9 c.936dupG p.L313fs Japan, Argentina Eriguchi et al., 2008
Anttonen et al., 2008
This study
Exon 9 c.947dupT p.R317fs Germany, Russia Senderek et al., 2005
This study
Intron 9 c.1029 + 1G4A p.V289_K343del Bosnia Senderek et al., 2005
Intron 9 c.1030-9G4A p.F345fs Norway, USA, Pakistan Anttonen et al., 2008
This study
Intron 9 c.1030-18G4A p.M344fs Germany Senderek et al., 2005
Exon 10 c.1035delC p.F345fs Germany This study
Exon 10 c.1126C4T p.Q376X Pakistan This study
Exon 10 c.1137C4A p.C379X Iraq This study
Exon 10 c.1240C4T p.Q414X Pakistan Riazuddin et al., 2009
Exon 10 c.1249C4T p.Q417X Mali Senderek et al., 2005
Exon 10 c.1276_1282delCAGGCTG p.Q426fs Germany This study
Exon 10 c.1312C4T p.Q438X Egypt Karim et al., 2006
Exon 10 c.1367delT p.L456fs Russia Senderek et al., 2005
Exon 10 c.1367T4A p.L456X Turkey Anttonen et al., 2008
Exon 10 c.1370T4C p.L457P Japan Anttonen et al., 2008
Exon, nucleotide and amino acid numbering is according to NM_022464.4 and NP_071909.1. Genomic coordinates are based on GRCh37/hg19.
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However, most mutations are private mutations identified in single
families only making diagnostic recommendations for selected
screening of exons or testing of selected mutations arguable.
Most pathogenic variants identified in this study and reported ear-
lier are micromutations affecting one or a few nucleotides.
Moreover, we and others (Takahata et al., 2010) found that the
SIL1 mutation spectrum also includes deletions of several kb of
DNA. Although it is conceivable that some patients without an
identified SIL1 mutation are compound heterozygous for non-
overlapping genomic deletions in the huge SIL1 gene (spanning
0.25 Mb of genomic DNA), data from whole-genome single
nucleotide polymorphism genotyping and copy number variation
analysis available for 29 out of the 46 SIL1 mutation-negative
patients (A. Roos and S. Spengler, unpublished data) showed no
genetic imbalances of the SIL1 gene that is covered by 115 mar-
kers on the microarrays used (Affymetrix GeneChip Genome-Wide
Human SNP 6.0-Array, Supplementary Fig. 1). Nevertheless, it is
probably warranted to extend future SIL1 mutation screening to
investigate the presence of pathogenic copy number aberrations.
In addition to mutations missed by commonly applied diagnostic
strategies there is evidence for locus heterogeneity as well. We
excluded linkage or homozygosity to the SIL1 region on chromo-
some 5 in four families with a typical Marinesco-Sjo¨gren syndrome
phenotype confirming that at least one additional locus does exist
(Families MSS96, MSS136, MSS144, MSS174). Others have
explored functional candidate genes for mutations in unclarified
Marinesco-Sjo¨gren syndrome cases without success (Anttonen
et al., 2008).
Although Marinesco-Sjo¨gren syndrome is caused by a wide
spectrum of SIL1 mutations, patients present with a relatively
homogeneous phenotype and show almost invariably the hallmark
clinical features of cerebellar atrophy and ataxia, cataracts, intel-
lectual disability and myopathy (Fig. 2). These somewhat contra-
dictory observations might be reconciled by the notion that all
SIL1 mutations are expected to eventually lead to loss of the pro-
tein or its critical functional domains. This has been predicted or
experimentally confirmed for most nonsense and frameshift muta-
tions, for two splice-site mutations resulting in in-frame deletions
(Senderek et al., 2005) and for mutations altering the very
C-terminus of the protein (Howes et al., 2012). In the present
study we have shown that a SIL1 missense mutation (p.G312R),
a two amino acid in-frame deletion (p.V231_I232del) and a
frameshift mutation in the last exon, which is predicted to
escape nonsense-mediated messenger RNA decay (p.Q426fs),
also result in a prominent reduction of SIL1 protein levels in cul-
tured lymphoblasts (Fig. 4). Although we cannot conclude from
these data that reduced protein levels are a general consequence
of seemingly ‘milder’ SIL1 mutations, such a mechanism might
exist for at least a subset of mutations, and for some it has
been experimentally shown that mutant proteins are particularly
Figure 2 Clinical presentation of patients with Marinesco-Sjo¨gren syndrome with identified SIL1 mutations. (A) Relative frequency of
signs and symptoms based on data compiled from our patient cohort and reports from the literature (Anttonen et al., 2005; Senderek
et al., 2005; Karim et al., 2006; Annesi et al., 2007; Anttonen et al., 2008; Eriguchi et al., 2008; Riazuddin et al., 2009; Takahata et al.,
2010; Terracciano et al., 2012). For details see Supplementary Tables 1 and 2. (B–D) Sagittal MRI scans of three patients with Marinesco-
Sjo¨gren syndrome showing marked cerebellar atrophy. (B) Patient MSS25.2 at age 14 years, T1-weighted image; (C) Patient MSS33.1 at
age 24 years, T1-weighted image; (D) Patient MSS87.1 at age 3 years, T1-weighted image.
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unstable and either form large aggregates in the endoplasmic
reticulum or are rapidly degraded through the proteasome
(Howes et al., 2012).
Our data confirm that the clinical triad of cataracts, cerebellar
atrophy and myopathy strongly suggests the presence of SIL1
mutations (detection rate 60%) whereas patients presenting with
variant phenotypes are unlikely to have SIL1 mutations (detection
rate 2.7%). The only mutation-positive case in the latter cohort
was a girl who had not developed cataracts until the age of
4 years (Patient MSS24.1). Two additional patients without cata-
racts (at age 1 and 4 years, respectively) have been reported
(Senderek et al., 2005; Terracciano et al., 2012). As the latest
reported onset of cataracts was in a 7-year-old girl in our cohort
(Patient MSS142.1), these patients are likely to develop cataracts
within the next few years. It has been noted previously that cata-
racts may develop unusually fast within a few weeks in patients
with Marinesco-Sjo¨gren syndrome (Ishikawa et al., 1993).
Therefore it might be appropriate to include infants and preschool
age children with cerebellar atrophy and myopathy without cata-
racts in SIL1 mutation screening while the full-blown phenotype
including cataracts should be expected after the age of 10 years.
Historical descriptions of patients with Marinesco-Sjo¨gren
syndrome stressed the presence of profound intellectual disability
in most cases (Mu¨ller, 1962; Hayabara et al., 1975). More recent
reports showed a large spectrum of mental impairment in
Marinesco-Sjo¨gren syndrome with most patients exhibiting only
mild cognitive impairment and only few cases with severe intel-
lectual deficits. In our cohort of patients with SIL1 mutations we
identified six cases with normal intellectual capacities but an other-
wise typical Marinesco-Sjo¨gren syndrome phenotype (Fig. 5).
Patients without intellectual disability should be considered for
SIL1 mutation analysis if their clinical presentation was compatible
with the diagnosis of Marinesco-Sjo¨gren syndrome.
The differential diagnosis of Marinesco-Sjo¨gren syndrome
includes several conditions featuring combinations of brain, skel-
etal muscle and eye abnormalities. Congenital cataracts, facial
dysmorphism, and neuropathy syndrome shares with Marinesco-
Sjo¨gren syndrome the features of cataracts and muscle weakness
or hypotonia. The presence of cerebellar atrophy in Marinesco-
Sjo¨gren syndrome and demyelinating neuropathy in congenital
cataracts, facial dysmorphism, and neuropathy syndrome distin-
guishes the two syndromes (Lagier-Tourenne et al., 2002).
Congenital cataracts, facial dysmorphism, and neuropathy syn-
drome is caused by a founder mutation in the CTDP1 gene
Figure 3 Histopathological and electron microscopic findings in skeletal muscle biopsies of patients with Marinesco-Sjo¨gren syndrome.
(A) Patient MSS33.1. Black arrows: abnormal nuclei and autophagic material. White arrow: normal myonucleus. Semi-thin section of
glutaraldehyde-fixed, epon-embedded tissue; toluidine blue. Scale bar = 20 mm. (B) Patient MSS87.1. Arrows: autophagic vacuoles in the
perinuclear sarcoplasm. Ultra-thin section of glutaraldehyde-fixed, epon-embedded tissue; electron microscopy. Scale bar = 3 mm.
(C) Patient MSS87.1. Black arrows: autophagic vacuoles in the perinuclear sarcoplasm of an atrophic muscle fibre. White arrows:
perinuclear osmiophilic membrane-like structure characteristic for Marinesco-Sjo¨gren syndrome. The myonucleus shows degenerative
condensation of chromatin. Electron microscopy. Scale bar = 2.5 mm. (D) Patient MSS33.1. Arrows: degenerating myonucleus ensheathed
by a prominent osmiophilic membrane-like structure. Electron microscopy. Scale bar = 1.5 mm.
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(Varon et al., 2003) that seems to be restricted to the Gypsy
population. In fact, two patients from our cohort of Marinesco-
Sjo¨gren syndrome-like cases, both of Gypsy origin and presenting
with congenital cataracts and a history of hypotonia, muscle
weakness and elevated creatine kinase levels initially suggesting
a myopathic process were found to carry the CTDP1 founder mu-
tation. Careful clinical and neurophysiological re-evaluation re-
vealed a demyelinating neuropathy as the cause of the
neuromuscular features (Patients MSS21.1 and MSS73.1,
Supplementary Table 3). Cerebrotendinous xanthomatosis is an
inherited disorder associated with the deposition of cholestanol
in the brain and other tissues and is characterized by progressive
cerebellar ataxia, cataracts, and tendineous or tuberous xanthomas
(Van Bogaert et al., 1937). The diagnosis can be made by elevated
serum cholestanol levels and identification of mutations in the
CYP27A1 gene (Cali et al., 1991). Importantly, cerebrotendinous
xanthomatosis is a treatable condition warranting proper diagnos-
tic measures to be taken (Berginer et al., 1984). One patient with
juvenile cataracts and neurological problems starting during ado-
lescence included in our series (Patient MSS48.1, Supplementary
Table 3) was found to have cerebrotendinous xanthomatosis.
Other differential diagnoses include ataxia-microcephaly-cataract
syndrome (Ziv et al., 1992), cataract-ataxia-deafness-retardation
syndrome (Begeer et al., 1991) and VLDLR-associated cerebellar
hypoplasia (Schurig et al., 1981; Boycott et al., 2005). Finally,
Marinesco-Sjo¨gren syndrome shares clinical features with mito-
chondrial disorders (Schapira, 2006) and disorders of defective
N- and O-glycosylation of proteins (Eklund and Freeze, 2006;
Muntoni et al., 2011). One of the SIL1 mutation-negative patients
in our series (Patient MSS53.1, Supplementary Table 3) was diag-
nosed with Sengers syndrome, a form of mitochondrial DNA de-
pletion disorder caused by an AGK gene mutation (Calvo et al.,
2012; Mayr et al., 2012).
To our knowledge, there are no comprehensive screening
studies that have explored a potential role of SIL1 mutations in
cohorts of patients with non-syndromic, isolated myopathy, cata-
racts or ataxia. However, we assume that SIL1 has only a minor
relevance in the screening of these patients. Data obtained using
whole-exome sequencing and next generation sequencing ataxia
panels (including all known genes for isolated or syndromic atax-
ias) did not reveal clearly pathogenic SIL1 alleles in a cohort of
490 patients with early-onset ataxia that had already been
screened negative for all common early-onset ataxia genes (i.e.
FXN, AOA2, AOA1, POLG), thus highly enriched for mutations
in rarer early onset ataxia genes (M. Synofzik and P. Bauer, un-
published data).
Muscle biopsies obtained from patients with Marinesco-Sjo¨gren
syndrome show various non-specific signs indicating degeneration
of skeletal muscle fibres. At the ultrastructural level, degenerating
myonuclei are occasionally surrounded by an electron-dense,
membrane-like structure (Herva et al., 1987; Sewry et al.,
1988). We have confirmed this finding in all muscle biopsies of
patients with Marinesco-Sjo¨gren syndrome that were available for
electron microscopy in this study (n = 4; MSS33.1, MSS87.1,
MSS91.1 and MSS94.1) and in our earlier report (n = 6)
(Senderek et al., 2005) suggesting that this finding is a character-
istic feature related to SIL1 pathology. In general, muscle biopsies
are considered invasive procedures that are best avoided if a diag-
nosis can be established using other methods. Although with the
availability of SIL1 sequencing there is no longer a diagnostic need
Figure 4 SIL1 mutations result in substantially decreased SIL1
protein levels. Immunoblot of SIL1 in immortalized lymphoblasts
of patients with Marinesco-Sjo¨gren syndrome. Cell lysates of
Patients MSS24, MSS32, MSS33, MSS64 and MSS94 and two
healthy control individuals were immunoblotted with an anti-
SIL1 antibody (top) and an anti-GAPDH antibody (as loading
control, bottom). SIL1 levels in patients’ lymphoblasts were se-
verely reduced compared to the levels in control subjects. Note
that seemingly ‘milder’ mutations [small in-frame deletion
(MSS24.1), missense mutation (MSS32.1) and frameshift
mutation in the last exon (MSS64.1)] have similar effects as
truncating mutations that are expected to lead to nonsense-
mediated messenger RNA decay (MSS33.1 and MSS94.1).
Figure 5 Patient MSS64.1 without intellectual disability but an
otherwise characteristic Marinesco-Sjo¨gren syndrome pheno-
type. (A) Brain MRI scan at age 20 months shows profound
atrophy of the cerebellum (T2-weighted image). (B) Cataract of
the right eye which developed within a few weeks at age 3.5
years. (C and D) Sonography of the M. quadriceps at the age of
6.75 years shows an increase in echogenicity, especially in the
area of the M. rectus femoris with poorly identifiable structures
of fascia and lack of echogenicity of the bone.
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for muscle biopsies in patients with Marinesco-Sjo¨gren syndrome
with typical symptoms, this procedure still may be important in the
diagnosis of Marinesco-Sjo¨gren syndrome, especially in less clear-
cut cases. First of all a muscle biopsy can be helpful in differentiat-
ing myopathy from other causes of hypotonia and weakness.
Secondly, the full Marinesco-Sjo¨gren syndrome phenotype might
not be seen in very young children as cataracts tend to develop
later making the differentiation from other causes of a cerebellar
syndrome and hypotonia more difficult. In addition, as parts of the
EMG procedure (to establish a myopathy) are uncomfortable and
not well tolerated by young children, results might be inconclusive.
In this scenario, electron microscopy of a muscle biopsy unveiling
vacuolar myopathy and the characteristic perinuclear membrane-
like structures can help to consider Marinesco-Sjo¨gren syndrome
as a differential diagnosis and can direct to SIL1 mutation analysis
(Terracciano et al., 2012).
The current study contributes to our understanding of the clinical
and genetic basis of Marinesco-Sjo¨gren syndrome. A molecular diag-
nosis was obtained in 60% of patients from a screening cohort of
25 unrelated index patients with a full-blown Marinesco-Sjo¨gren
syndrome phenotype leaving a considerable proportion of patients
without genetic diagnosis to date. This further underscores the fact
that other still unknown mutations must exist in known or unknown
disease associated genes. As a co-chaperone for BiP, SIL1 is involved
in protein synthesis and quality control in the endoplasmic reticulum.
Thus, secretory pathway proteins not properly processed or not
reaching their site of action in SIL1 deficient cells will represent
plausible functional candidates. No such factors have been identified
so far, but appropriate tools for proteomic analysis of cell compart-
ments and cell surface proteins are now at hand. Combining such
data with data obtained by high-throughput DNA sequencing pro-
jects in non-SIL1 Marinesco-Sjo¨gren syndrome families will likely
disclose the missing Marinesco-Sjo¨gren syndrome gene(s) within
the next few years and may also hold promise to identify potential
therapeutic targets.
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